Patents Assigned to Xoma Corporation
  • Patent number: 7081334
    Abstract: The present invention provides a method for quantifying the presence of extracellular LBP in body fluids including blood in a subject comprising conducting an LBP immunoassay on plasma obtained from said subject.
    Type: Grant
    Filed: November 26, 2001
    Date of Patent: July 25, 2006
    Assignee: Xoma Corporation
    Inventors: Mark Leslie White, Stephen Fitzhugh Carroll, Jeremy Kam-kuen Ma
  • Publication number: 20050118112
    Abstract: The present invention relates to methods for treating a subject suffering from infection with Mycobacteria, such as M. leprae or M. tuberculosis comprising administering to the subject a composition comprising a bactericidal/permeability-inducing (BPI) protein product alone or in combination with administration of an anti-Mycobacterial antibiotic.
    Type: Application
    Filed: September 8, 2003
    Publication date: June 2, 2005
    Applicant: XOMA CORPORATION
    Inventor: Lewis Lambert
  • Patent number: 6828418
    Abstract: Disclosed are novel bactericidal/permeability-increasing (BPI) protein products wherein cysteine residue number 132 or 135 is replaced by another amino acid residue, preferably an alanine or serine residue and/or wherein the leucine residue at position 193 is the carboxy terminal residue. Also disclosed are DNA sequences encoding methods for the production of the same in appropriate host cells, and stable homogeneous pharmaceutical compositions containing the analogs suitable for use treatment of gram negative bacterial infection and its sequelae.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: December 7, 2004
    Assignee: Xoma Corporation
    Inventors: Georgia Theofan, Arnold Horwitz, David Burke, Manik Baltaian, Lynn Grinna
  • Patent number: 6767893
    Abstract: The present invention provides methods of treating adverse physiological effects associated with intestinal ischemia/reperfusion by administering to a subject suffering from the effects of intestinal ischemia/reperfusion an effective amount of a BPI protein product.
    Type: Grant
    Filed: October 12, 1999
    Date of Patent: July 27, 2004
    Assignee: Xoma Corporation
    Inventors: William Steve Ammons, Károly M. Mészäros
  • Patent number: 6759203
    Abstract: The present invention provides a method for quantifying the presence of extracellular BPI in body fluids including blood in a subject comprising conducting a BPI immunoassay on body fluid sample obtained from said subject.
    Type: Grant
    Filed: October 9, 1998
    Date of Patent: July 6, 2004
    Assignee: XOMA Corporation
    Inventors: Mark Leslie White, Stephen Fitzhugh Carroll, Jeremy Kam-kuen Ma
  • Publication number: 20040023884
    Abstract: The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and variants of the sequence or subsequence thereof, having at least one of the BPI biological activities, such as heparin binding, heparin neutralization, LPS binding, LPS neutralization or bactericidal activity. The invention provides peptides and pharmaceutical compositions of such peptides for a variety of therapeutic uses.
    Type: Application
    Filed: May 27, 2003
    Publication date: February 5, 2004
    Applicant: XOMA Corporation
    Inventor: Roger G. Little
  • Patent number: 6686332
    Abstract: The present invention provides methods of treating adverse physiological effects associated with depressed reticuloendothelial system function comprising administering to a subject suffering from depressed reticuloendothelial system function an effective amount of a BPI protein product.
    Type: Grant
    Filed: October 12, 2000
    Date of Patent: February 3, 2004
    Assignee: Xoma Corporation
    Inventors: Paul A. M. van Leeuwan, Marja A. Boermeester
  • Publication number: 20030236187
    Abstract: Novel LBP compositions and therapeutic uses for LBP are provided for preventing the adverse effects of exposure to endotoxin.
    Type: Application
    Filed: October 23, 2001
    Publication date: December 25, 2003
    Applicant: XOMA Corporation
    Inventors: Russell L. Dedrick, Stephen F. Carroll
  • Patent number: 6664231
    Abstract: The present invention relates generally to anti-fungal peptides derived from or based on Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI) and in vivo or in vitro uses of such peptides.
    Type: Grant
    Filed: October 2, 2000
    Date of Patent: December 16, 2003
    Assignee: Xoma Corporation
    Inventors: Roger G. Little, II, Edward Lim, Mitchell B. Fadem
  • Patent number: 6620785
    Abstract: The present invention relates to methods for treating a subject suffering from infection with Mycobacteria, such as M. leprae or M. tuberculosis comprising administering to the subject a composition comprising a bactericidal/permeability-inducing (BPI) protein product alone or in combination with administration of an anti-Mycobacterial antibiotic.
    Type: Grant
    Filed: February 13, 2001
    Date of Patent: September 16, 2003
    Assignee: Xoma Corporation
    Inventor: Lewis H. Lambert, Jr.
  • Patent number: 6599881
    Abstract: Antithrombotic materials and methods are provided for the treatment of thrombotic disorders, in which therapeutically effective amounts of BPI protein products are administered.
    Type: Grant
    Filed: July 6, 2000
    Date of Patent: July 29, 2003
    Assignee: Xoma Corporation
    Inventors: Mark L. White, William Steve Ammons
  • Patent number: 6599880
    Abstract: Novel BPI deletion analogs are provided that consist of amino acid residues 10 through 193 of mature human BPI wherein the cysteine residue at BPI amino acid position 132 is replaced by another amino acid. Fusion proteins comprising these analogs are also provided, as are polynucleotides encoding these products, materials and methods for their recombinant production, compositions and medicaments of these products, and therapeutic uses for these products.
    Type: Grant
    Filed: May 25, 2000
    Date of Patent: July 29, 2003
    Assignee: Xoma Corporation
    Inventors: Arnold Horwitz, Stephen F. Carroll, David Burke
  • Patent number: 6596691
    Abstract: Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.
    Type: Grant
    Filed: November 30, 2000
    Date of Patent: July 22, 2003
    Assignee: XOMA Corporation
    Inventors: Brett P. Giroir, Patrick J. Scannon
  • Patent number: 6586400
    Abstract: Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytokines, fibrinolysis and coagulation factors and changes in lymphocyte counts are observed upon such treatment. Also observed is alleviation of endotoxin mediated decreases in systemic vascular resistance index (SVRI) and concomitant increases in cardiac index (CI).
    Type: Grant
    Filed: December 8, 2000
    Date of Patent: July 1, 2003
    Assignee: Xoma Corporation
    Inventors: Nadav Friedmann, Patrick J. Scannon, Sander J. H. van Deventer, Marijke A. M. von der Mohlen, Nancy Wedel
  • Patent number: 6583116
    Abstract: The present invention relates to methods for treating chlamydial infection comprising administering to a subject suffering from a chlamydial infection a bactericidal permeability-inducing (BPI) protein product.
    Type: Grant
    Filed: October 30, 2000
    Date of Patent: June 24, 2003
    Assignee: Xoma Corporation
    Inventor: Lewis H. Lambert, Jr.
  • Publication number: 20030017986
    Abstract: The present invention provides methods of treating a subject suffering from adverse effects, complications or conditions, associated with or resulting from a corneal injury including, corneal infection or ulceration, by topical administration of suitable ophthalmic preparations of bactericidal/permeability-increasing (BPI) protein products.
    Type: Application
    Filed: August 22, 2002
    Publication date: January 23, 2003
    Applicant: XOMA Corporation
    Inventor: Patrick J. Scannon
  • Patent number: 6482796
    Abstract: Improved therapeutic uses for N-terminal BPI protein products are described in patients that have BPI-reactive anti-neutrophil cytoplasmic antibodies.
    Type: Grant
    Filed: February 22, 1999
    Date of Patent: November 19, 2002
    Assignee: Xoma Corporation
    Inventor: Stephen Fitzhugh Carroll
  • Publication number: 20020128191
    Abstract: The present invention provides methods of treating a subject suffering from adverse effects, complications or conditions, associated with or resulting from a corneal injury including, corneal infection or ulceration, by topical administration of suitable ophthalmic preparations of bactericidal/permeability-increasing (BPI) protein products.
    Type: Application
    Filed: August 27, 2001
    Publication date: September 12, 2002
    Applicant: XOMA Corporation
    Inventor: Patrick J. Scannon
  • Publication number: 20020127622
    Abstract: The present invention provides a method for quantifying the presence of extracellular LBP in body fluids including blood in a subject comprising conducting an LBP immunoassay on plasma obtained from said subject.
    Type: Application
    Filed: November 26, 2001
    Publication date: September 12, 2002
    Applicant: XOMA Corporation
    Inventors: Mark Leslie White, Stephen Fitzhugh Carroll, Jeremy Kam-Kuen Ma
  • Publication number: 20020119930
    Abstract: Novel LBP compositions and therapeutic uses for LBP are provided for preventing the adverse effects of exposure to endotoxin.
    Type: Application
    Filed: October 23, 2001
    Publication date: August 29, 2002
    Applicant: XOMA Corporation
    Inventors: Russell L. Dedrick, Stephen F. Carroll